Urothelial bladder cancer: Biomarkers for detection and screening

BJU International

Volumn 102, Issue 9B, 2008, Pages 1234-1241

  Konety, Badrinath ^a   Lotan, Yair ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; TUMOR MARKER;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC KIT; DISEASE MARKER; HUMAN; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY;

FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATINS; MALE; MASS SCREENING; NUCLEAR PROTEINS; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 54049104345     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07965.x     Document Type: Review

References (90)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945 18 : 519 20
3. Paez A, Coba JM, Murillo N et al. Reliability of the routine cytological diagnosis in bladder cancer. Eur Urol 1999 35 : 228 32
4. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002 167 : 75 9
5. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003 61 : 109 18
6. Keesee SK, Briggman JV, Thill G et al. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 1996 6 : 189 214
7. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002 167 : 80 3
8. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005 293 : 810 6
9. Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006 295 : 299 305
10. Miyanaga N, Akaza H, Ishikawa S et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997 31 : 163 8
11. Atsu N, Ekici S, Oge OO et al. False-positive results of the NMP22 test due to hematuria. J Urol 2002 167 : 555 8
12. Ishii T, Okadome A, Takeuchi F et al. Urinary levels of nuclear matrix protein 22 in patients with urinary diversion. Urology 2001 58 : 940 2
13. Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. BJU Int 2007 177 : 1636 45
14. Tritschler S, Scharf S, Karl A et al. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 2007 51 : 403 8
15. Malkowicz SB. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 2000 27 : 63 73
16. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 2006 24 : 326 37
17. Landman J, Chang Y, Kavaler E et al. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998 52 : 398 402
18. Johnston B, Morales A, Emerson L et al. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997 158 : 2098 101
19. Oge O, Atsu N, Sahin A et al. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer. Scand J Urol Nephrol 2000 34 : 349 51
20. Zimmerman RL, Bagley D, Hawthorne C et al. Utility of the Bard BTA test in detecting upper urinary tract transitional cell carcinoma. Urology 1998 51 : 956 8
21. Raitanen MP, Hellström P, Marttila T et al. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test. Eur Urol 2001 40 : 422 6
22. TM. Can J Urol 1997 4 : 400 5
23. Fradet Y, LaRue H, Parent-Vaugeois C et al. Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. Int J Cancer 1990 46 : 990 7
24. Fradet Y, Islam N, Boucher L et al. Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proc Natl Acad Sci USA 1987 84 : 7227 31
25. Allard P, Fradet Y, Tetu B et al. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1995 1 : 1195 202
26. Vriesema JL, Atsma F, Kiemeney LA et al. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 2001 58 : 367 71
27. Lodde M, Mian C, Wiener H et al. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology 2001 58 : 362 6
28. Piaton E, Daniel L, Verriele V et al. Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study. Lab Invest 2003 83 : 845 52
29. Lodde M, Mian C, Negri G et al. Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology 2003 61 : 243 7
30. Feil G, Zumbragel A, Paulgen-Nelde HJ et al. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Anticancer Res 2003 23 : 963 7
31. Messing EM, Teot L, Korman H et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 2005 174 : 1238 41
32. Mian C, Maier K, Comploj E et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006 108 : 60 5
33. Pfister C, Chautard D, Devonec M et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003 169 : 921 4
34. Lodde M, Mian C, Comploj E et al. The uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 2006 67 : 950 4
35. Mian C, Lodde M, Comploj E et al. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res 2005 25 : 3641 4
36. Cajulis RS, Haines GK 3rd, Frias-Hidvegi D et al. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 1995 13 : 214 23
37. Placer J, Espinet B, Salido M et al. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002 42 : 547 52
38. Toma MI, Friedrich MG, Hautmann SH et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004 22 : 145 9
39. Varella-Garcia M, Akduman B, Sunpaweravong P et al. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol 2004 22 : 16 9
40. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002 168 : 1950 4
41. Schwarz S, Rechenmacher M, Filbeck T et al. Value of multicolor fluorescence in situ hybridization (Urovysion TM) in the differential diagnosis of flat urothelial lesions. J Clin Pathol 2008 61 : 272 7
42. Bergman J, Reznichek RC, Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int 2008 101 : 26 9
43. Zellweger T, Benz G, Cathomas G et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006 119 : 1660 5
44. Skacel M, Fahmy M, Brainard JA et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003 169 : 2101 5
45. Yoder BJ, Skacel M, Hedgepeth R et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007 127 : 295 301
46. Bollmann M, Heller H, Bankfalvi A et al. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005 95 : 1219 25
47. Mian C, Lodde M, Comploj E et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006 59 : 984 7
48. Pycha A, Mian C, Hofbauer J et al. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998 159 : 265 9
49. Gudjonsson S, Isfoss BL, Hansson K et al. The value of the UroVysion(R) assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007 54 : 402 8
50. Daniely M, Rona R, Kaplan T et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and followup of bladder cancer in patients with benign urine cytology. Cancer 2007 111 : 517 24
51. Kipp BR, Karnes RJ, Brankley SM et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005 173 : 401 4
52. Mengual L, Marin-Aguilera M, Ribal MJ et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with Bacillus Calmette-Guerin therapy. Eur Urol 2007 52 : 752 9
53. Whitson J, Greene KG, Carroll PR, Konety BR. Decreasing time to detection: use of fluorescence in situ hybridization in patients with high risk superficial bladder tumors undergoing intravesical therapy. J Urol 2008 179 : 69
54. Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Asfaq S. Prospective Evaluation of the clinical utility of reflex fluorescence in situ hybridization assay in patients with atypical cytology for detection of urothelial carcinoma of the bladder. J Urol 2008 179 : 2164 9
55. Olweny E, Garcia M, Carroll PR, Konety BR. FISH vs. cytology in post cystectomy surveillance. J Urol 2008 179 : 69
56. Southgate J, Harnden P, Trejdosiewicz LK. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol 1999 14 : 657 64
57. Mungan NA, Vriesema JL, Thomas CM et al. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology 2000 56 : 787 92
58. Schroeder GL, Lorenzo-Gomez MF, Hautmann SH et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004 172 : 1123 6
59. Sanchez-Carbayo M, Urrutia M, Silva JM et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001 165 : 1462 7
60. Pariente JL, Bordenave L, Jacob F et al. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol 2000 163 : 1116 9
61. Nisman B, Barak V, Shapiro A et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002 94 : 2914 22
62. Nisman B, Biran H, Heching N et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 2008 98 : 77 9
63. Fernandez-Gomez J, Rodriguez-Martinez JJ, Barmadah SE et al. Urinary CYFRA 21-1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 2007 51 : 1267 74
64. NCI. NCI Cancer Screening Overview. Available at: http://www.cancer.gov/ cancerinfo/pdq/screening/overview. Accessed April 2008
65. Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992 148 : 788 90
66. Messing EM, Young TB, Hunt VB et al. Hematuria home screening: repeat testing results. J Urol 1995 154 : 57 61
67. Messing EM, Young TB, Hunt VB et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995 45 : 387 96
68. Messing EM, Madeb R, Young T et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006 107 : 2173 9
69. Mayfield MP, Whelan P. Bladder tumours detected on screening: results at 7 years. Br J Urol 1998 82 : 825 8
70. American College of Surgeons. Commission on Cancer National Cancer Database. Available at: http://www.facs.org/cancer/ncdb/index.html. Accessed September 2008
71. Anonymous. Surveillance, Epidemiology and End Results (SEER) Program (http://www.seer.cancer.gov). SEER Stat Database. Incidence - SEER 9 Regs Public-Use. Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. November 2004
72. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001 19 : 666 75
73. Lotan Y, Gupta A, Shariat SF et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005 23 : 6533 9
74. Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol 2004 172 : 1822 4
75. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992 6 : 1 30
76. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000 89 : 630 9
77. Samanic C, Kogevinas M, Dosemeci M et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 2006 15 : 1348 54
78. Lotan Y, Shariat SF NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 2008 101 : 1362 7
79. Sarosdy MF, Kahn PR, Ziffer MD et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006 176 : 44 7
80. Hemstreet GP 3rd, Yin S, Ma Z et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001 93 : 427 36
81. Wu X, Lin J, Grossman HB et al. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol 2007 25 : 4974 81
82. Benoit RM, Gronberg H, Naslund MJ. A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer Prostatic Dis 2001 4 : 138 45
83. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002 137 : 132 41
84. Redaelli A, Cranor CW, Okano GJ, Reese PR. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 2003 21 : 1213 38
85. Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies. JAMA 1995 274 : 881 4
86. Shen Y, Parmigiani G. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev 2005 14 : 529 32
87. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. Cancer 2006 107 : 982 90
88. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 2006 24 : 338 43
89. Ma F, Fleming LE, Lee DJ et al. Mortality in Florida professional firefighters 1972-99. Am J Ind Med 2005 47 : 509 17
90. Greene KG, Konety BR, Stoller M. Results from the San Francisco Firefighters bladder cancer screening study. J Urol 2008 179 : 323